Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Has Consensus Price Target of $46.67 According to Analysts

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $46.67.

NBTX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Guggenheim initiated coverage on shares of Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective for the company.

Nanobiotix Price Performance

NASDAQ:NBTX opened at $32.03 on Tuesday. The company has a 50 day simple moving average of $31.00 and a two-hundred day simple moving average of $33.99. Nanobiotix has a fifty-two week low of $19.14 and a fifty-two week high of $57.14.

Nanobiotix Company Profile

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy.

Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.